Cite
HARVARD Citation
Arija, J. et al. (n.d.). 2638 Effectiveness of 2nd-line and subsequent therapies after pazopanib (Paz) in patients (pt) with metastatic renal cell carcinoma (mRCC): Final results of the SPAZO study (SOGUG). European journal of cancer. pp. S526-. [Online].